Deals
Having secured deals with AstraZeneca and Novartis, Niowave is constructing a second facility to meet rising demand for actinium-225, which can be used to develop next-generation radiopharmaceuticals.
FEATURED STORIES
European pharma companies splashed billions of dollars into the U.S. biopharma sector in a matter of days, but there are differing views on whether the activity represents the rise of a new buyer class or a quirk of timing.
After years of suffering from a bear market and more than 14 months of geopolitical turmoil shaking the macroenvironment, biotech appears to be moving on.
With six acquisitions already this year, Eli Lilly’s business development shows no signs of stopping as executives make good on a promise to spend their GLP-1 gains.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Chinese biotech company Ascletis Pharma debuted on the Hong Kong stock exchange, rising as much as 6.4 percent, but ending the day where it started.
The Cancer Prevention Institute of California (CPIC), located in Fremont, California, announced it was disbanding after 44 years. The reason for the closing, it indicates, is lack of federal funding.
Only a matter of days after Roche filed its second-quarter financial report, it’s had plenty of news to report.
In March, San Diego-based Orexigen Therapeutics filed for bankruptcy. Back in April, Orexigen entered into an asset purchase deal with Nalpropion Pharmaceuticals to sell most of its assets, subject to court approval.
Liquidia Technologiesnlaunched a successful initial public offering on July 25, raising $50 million. Neal Fowler, the company’s chief executive officer, and Kevin Gordon, Liquidia’s president and chief financial officer, took time out to talk with BioSpace about the company and where it’s headed.
Many analysts and investors were holding their breaths, waiting to see what Biogen would say at yesterday’s second-quarter financial report. The financials weren’t the focus, however, but what the Cambridge, Massachusetts biotech had to say about its pipeline, especially for Alzheimer’s disease, was.
Shares of Nabriva Therapeutics are rising this morning after the company announced it acquired privately-held Zavante Therapeutics.
Biogen reported strong sales for the second quarter, with total revenues of $3.4 billion, up 9 percent compared to the same period in 2017.
Shares of Eli Lilly jumped in premarket trading after the company reported total revenue of $6.35 billion for the second quarter, a 9 percent increase in revenue over the same period last year.
So far in 2018, it’s been a good year for biotech initial public offerings (IPOs). According to a Crunchbase News article, in the second quarter of this year alone, there were at least 16 U.S. venture-backed biotech and healthcare IPOs—compared to only 11 tech IPOs in the same period.